LSRII flow lasers: photo by David Parks

LSRII flow lasers: photo by David Parks



In addition to our main research projects, we have ongoing collaborations with laboratories in the US and abroad. Join us to participate in these and other new research projects we are setting up with our colleagues at Emory and Georgia Tech!


Nakauchi lab | University of tokyo and stanford

We have been working with Dr. Hiro Nakauchi’s laboratory to characterize the potential of single HSCs to regenerate the various types of immune cells in vivo. Currently, we are working in another very exciting project to engineer new mice from induced pluripotent stem cells (iPSC) that are developed from different subsets of B lymphocytes. These studies will provide new insights into the epigenetic program that governs the development and function of the various types of antibody-producing cells.


roan lab | UCSf

We are working with Dr. Nadia Roan’s laboratory to characterize tissue-resident B lymphocytes that reside in mucosal tissues, particularly in the female reproductive tract. Our goal is to understand the development and function of B lymphocytes that reside in tissues, in contrast to blood, and assess their role in both maintaining tissue homeostasis and responding to pathogens. 


mellins lab | stanford

We are working with Dr. Elizabeth (Betsy) Mellins to determine the functional impact of B-cell antigen presentation in promoting homeostasis, protective immune responses, and immunopathology. Currently, we are characterizing the roles of the MHC-II/HLA, H2-DM, and H2-DO molecules in the development and function of the various subsets of B cells, including tissue-resident B-1a, follicular B-2, marginal zone B, plasma cells, and developing B cells. 


smith lab | stanford

In collaboration with Dr. Bryan Smith, we have developed a novel nanomedicine technology with potential application in the diagnostic and treatment of cancer and atherosclerosis. We showed that single-walled carbon nanotubes (SWNT) are selectively internalized by mouse and human inflammatory monocytes, which then carry the SWNTs to inside the tumors and atherosclerotic plaques. Currently, we are using SWNTs to modulate the fate of inflammatory monocytes as an immune-therapy approach to treat various pathologies, including cancer.